Steven Batki, MD

Title(s)Professor, Psychiatry
SchoolSchool of Medicine
Address4150 Clement Street
San Francisco CA 94121
Phone415-221-4810 ext. 23671
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine

    Collapse Overview 
    Collapse Overview
    Steven L. Batki, M.D. is Professor of Psychiatry, in Residence, at the University of California, San Francisco (UCSF) School of Medicine and Chief of the Substance Abuse Programs and Director of the Addiction Psychiatry Research Program at the San Francisco VA Medical Center (SFVAMC), where he also directs the UCSF Addiction Psychiatry Fellowship Program. Dr. Batki is engaged in addiction research, training, and clinical services.

    Dr. Batki’s research and clinical interests include pharmacologic treatment for addiction to alcohol, opioids, and stimulants. His work focuses on psychiatric and medical disorders that co-occur with addiction, such as such as PTSD, traumatic brain injury (TBI), schizophrenia, and HIV/HCV. He has published extensively on clinical research in addiction and co-occurring disorders. He chaired the SAMSHA CSAT Treatment Improvement Protocol No. 37, Substance Abuse Treatment for Persons with HIV/AIDS, and Treatment Improvement Protocol No. 43, Medication-Assisted Treatment for Opioid Dependence.

    Dr. Batki's current research is supported by the Department of Defense and NIDA. His DoD projects are examining the effectiveness of pharmacotherapy for alcohol use disorders in veterans with posttraumatic stress disorder (PTSD) as well as in veterans with mild traumatic brain injury (TBI). Dr. Batki is also conducting NIDA-funded research on the pharmacotherapy of methamphetamine dependence. Recently completed NIDA and NIAAA work has included the study of hepatitis C treatment in injection drug users and the pharmacological treatment of alcohol dependence in schizophrenia.

    Collapse Research 
    Collapse Research Activities and Funding
    Non-Invasive Neuromodulation Device for the Treatment of Alcohol Use Disorder
    NIH R44AA027188Sep 20, 2018 - May 31, 2023
    Role: Co-Principal Investigator
    Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r
    NIH R01DA034527Feb 1, 2013 - Jan 31, 2019
    Role: Co-Principal Investigator
    Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B
    NIH R01DA031678Jun 1, 2011 - Jul 31, 2017
    Role: Co-Principal Investigator
    Improving Hepatitis C Treatment in Injection Drug Users
    NIH R01DA016764Sep 26, 2003 - Jun 30, 2010
    Role: Principal Investigator
    Naltrexone Treatment of Alcohol Abuse in Schizophrenia
    NIH R01AA013655Apr 1, 2003 - Mar 31, 2009
    Role: Principal Investigator
    NIH R01DA011397Feb 20, 1998 - Dec 31, 2002
    Role: Principal Investigator
    Treatment for Complex Patients: Continuing and Extended Care
    NIH P50DA009253Sep 29, 1994 - May 31, 2016
    Role: Co-Investigator
    NIH R01DA008526Aug 1, 1994 - Jun 30, 1998
    Role: Principal Investigator
    NIH P50DA001696Feb 1, 1978 - Aug 31, 2000
    Role: Co-Investigator
    General Clinical Research Center
    NIH M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Working memory and alcohol demand relationships differ according to PTSD symptom severity among veterans with AUD. Exp Clin Psychopharmacol. 2021 Apr; 29(2):166-177. Abram SV, Batki SL, Pennington DL. PMID: 34043400.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep. 2020 10 13; 43(10). Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. PMID: 32303763.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    3. A randomized pilot trial of topiramate for alcohol use disorder in veterans with traumatic brain injury: Effects on alcohol use, cognition, and post-concussive symptoms. Drug Alcohol Depend. 2020 09 01; 214:108149. Pennington DL, Bielenberg J, Lasher B, Herbst E, Abrams G, Novakovic-Agopian T, Batki SL. PMID: 32712569.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. JAMA Psychiatry. 2020 03 01; 77(3):246-255. Coffin PO, Santos GM, Hern J, Vittinghoff E, Walker JE, Matheson T, Santos D, Colfax G, Batki SL. PMID: 31825466.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    5. Care of the Transgender Patient. Ann Intern Med. 2019 11 19; 171(10):775. Herbst ED, Harris E, Pennington DL, Batki SL. PMID: 31739319.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Effects of Oxytocin Administration on Cue-Induced Craving in Co-occurring Alcohol Use Disorder and PTSD: A Within-Participant Randomized Clinical Trial. Alcohol Clin Exp Res. 2019 12; 43(12):2627-2636. Stauffer CS, Meinzer NK, Morrison T, Wen JH, Radanovich L, Leung D, Niles A, O'Donovan A, Batki SL, Woolley JD. PMID: 31610033.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. An electronic intervention to improve safety for pain patients co-prescribed chronic opioids and benzodiazepines. Subst Abus. 2018; 39(4):441-448. Zaman T, Rife TL, Batki SL, Pennington DL. PMID: 29595408.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Mobile Technology for Treatment Augmentation in Veteran Smokers With Posttraumatic Stress Disorder. Am J Prev Med. 2018 Jan; 54(1):124-128. Herbst E, Pennington D, Kuhn E, McCaslin SE, Delucchi K, Batki SL, Dickter B, Carmody T. PMID: 29074319.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    9. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial. Addiction. 2018 02; 113(2):268-278. Coffin PO, Santos GM, Hern J, Vittinghoff E, Santos D, Matheson T, Colfax G, Batki SL. PMID: 28734107.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    10. Race/ethnicity, education, and age are associated with engagement in ecological momentary assessment text messaging among substance-using MSM in San Francisco. J Subst Abuse Treat. 2017 04; 75:43-48. Turner CM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Batki S, Santos GM. PMID: 28237053.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    11. Observational Evidence for Buprenorphine's Impact on Posttraumatic Stress Symptoms in Veterans With Chronic Pain and Opioid Use Disorder. J Clin Psychiatry. 2016 09; 77(9):1182-1188. Seal KH, Maguen S, Bertenthal D, Batki SL, Striebel J, Stein MB, Madden E, Neylan TC. PMID: 27035058.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    12. Relations Between Cognitive Functioning and Alcohol Use, Craving, and Post-Traumatic Stress: An Examination Among Trauma-Exposed Military Veterans With Alcohol Use Disorder. Mil Med. 2016 07; 181(7):663-71. Heinz AJ, Pennington DL, Cohen N, Schmeling B, Lasher BA, Schrodek E, Batki SL. PMID: 27391620.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study. Psychopharmacology (Berl). 2016 07; 233(13):2571-80. Woolley JD, Arcuni PA, Stauffer CS, Fulford D, Carson DS, Batki S, Vinogradov S. PMID: 27137199.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    14. Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men. . 2016 May 01; 72(1):21-30. Santos GM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Hahn JA, Vlahov D, Vittinghoff E, Batki SL. PMID: 26674372.
      View in: PubMed   Mentions:
    15. What is the right pharmacotherapy for alcohol use disorder in patients with schizophrenia? J Clin Psychiatry. 2015 Oct; 76(10):e1336-7. Batki SL. PMID: 26528663.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. J Psychiatr Res. 2015 Oct; 69:150-7. Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. PMID: 26343607.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    17. Behavioral treatment of insomnia in early recovery. J Addict Med. 2014 Nov-Dec; 8(6):395-8. Kaplan KA, McQuaid J, Batki SL, Rosenlicht N. PMID: 25369939.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    18. A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder. Psychiatry Res. 2014 Dec 30; 224(3):281-7. Pennington DL, Abé C, Batki SL, Meyerhoff DJ. PMID: 25444536.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    19. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. Alcohol Clin Exp Res. 2014 Aug; 38(8):2169-77. Batki SL, Pennington DL, Lasher B, Neylan TC, Metzler T, Waldrop A, Delucchi K, Herbst E. PMID: 25092377.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    20. Cognitive-behavioral therapy in depressed primary care patients with co-occurring problematic alcohol use: effect of telephone-administered vs. face-to-face treatment-a secondary analysis. J Psychoactive Drugs. 2014 Apr-Jun; 46(2):85-92. Kalapatapu RK, Ho J, Cai X, Vinogradov S, Batki SL, Mohr DC. PMID: 25052784.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. Am J Psychiatry. 2014 Apr; 171(4):391-4. Batki SL, Pennington DL. PMID: 24687193.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    22. Alcohol use biomarkers predicting cognitive performance: a secondary analysis in veterans with alcohol dependence and posttraumatic stress disorder. Mil Med. 2013 Sep; 178(9):974-80. Kalapatapu RK, Delucchi KL, Lasher BA, Vinogradov S, Batki SL. PMID: 24005546.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. J Clin Psychopharmacol. 2013 Apr; 33(2):243-7. Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL. PMID: 23422399.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    24. Team-based learning exercise efficiently teaches brief intervention skills to medicine residents. Subst Abus. 2013; 34(4):344-9. Wamsley MA, Julian KA, O'Sullivan P, McCance-Katz EF, Batki SL, Satre DD, Satterfield J. PMID: 24159904.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    25. Relationship of age to impulsivity and decision making: a baseline secondary analysis of a behavioral treatment study in stimulant use disorders. J Addict Dis. 2013; 32(2):206-16. Kalapatapu RK, Lewis DF, Vinogradov S, Batki SL, Winhusen T. PMID: 23815427.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    26. Using standardized patients to evaluate screening, brief intervention, and referral to treatment (SBIRT) knowledge and skill acquisition for internal medicine residents. Subst Abus. 2012; 33(3):303-7. Satterfield JM, O'Sullivan P, Satre DD, Tsoh JY, Batki SL, Julian K, McCance-Katz EF, Wamsley M. PMID: 22738010.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    27. Accuracy of self-reported medical problems in patients with alcohol dependence and co-occurring schizophrenia or schizoaffective disorder. Schizophr Res. 2011 Nov; 132(2-3):190-3. Meszaros ZS, Dimmock JA, Ploutz-Snyder R, Chauhan SV, Abdul-Malak Y, Middleton FA, Batki SL. PMID: 21852074.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. Predictors of smoking severity in patients with schizophrenia and alcohol use disorders. Am J Addict. 2011 Sep-Oct; 20(5):462-7. Meszaros ZS, Dimmock JA, Ploutz-Snyder RJ, Abdul-Malak Y, Leontieva L, Canfield K, Batki SL. PMID: 21838846.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    29. Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment. Am J Addict. 2011 Jul-Aug; 20(4):312-8. Batki SL, Canfield KM, Ploutz-Snyder R. PMID: 21679262.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    30. Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study. J Addict Dis. 2010 Jul; 29(3):359-69. Batki SL, Canfield KM, Smyth E, Ploutz-Snyder R, Levine RA. PMID: 20635285.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    31. The description and evaluation of the implementation of an integrated healthcare model. Fam Syst Health. 2010 Jun; 28(2):146-60. Funderburk JS, Sugarman DE, Maisto SA, Ouimette P, Schohn M, Lantinga L, Wray L, Batki S, Nelson B, Coolhart D, Strutynski K. PMID: 20695672.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    32. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol. 2010 Jun; 69(6):578-92. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. PMID: 20565449.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansAnimals
    33. Pregabalin treatment of anxiety in patients with substance use disorders. Ann Pharmacother. 2010 May; 44(5):937-8. Raza S, Siddiqui UA, Megna JL, Schwartz TL, Batki SL. PMID: 20388860.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. Subst Use Misuse. 2010 Mar; 45(4):496-514. Canfield KM, Smyth E, Batki SL. PMID: 20141461.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    35. Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection. Drug Alcohol Depend. 2009 May 01; 101(3):176-82. Batki SL, Canfield KM, Smyth E, Ploutz-Snyder R. PMID: 19233573.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    36. Patient and provider attitudes towards monitored naltrexone treatment of alcohol dependence in schizophrenia. Am J Drug Alcohol Abuse. 2009; 35(5):273-8. Leontieva L, Dimmock J, Cavallerano M, DeRycke S, Meszaros Z, Carey K, Ploutz-Snyder R, Batki SL. PMID: 19591067.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res. 2009 Feb; 107(2-3):139-46. Batki SL, Meszaros ZS, Strutynski K, Dimmock JA, Leontieva L, Ploutz-Snyder R, Canfield K, Drayer RA. PMID: 19022627.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    38. Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia. Schizophr Res. 2008 Oct; 105(1-3):201-7. Batki SL, Leontieva L, Dimmock JA, Ploutz-Snyder R. PMID: 18701256.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    39. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008 Apr 01; 94(1-3):199-206. Gruber VA, Delucchi KL, Kielstein A, Batki SL. PMID: 18243585.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    40. Voucher-based incentives for naltrexone treatment attendance in schizophrenia and alcohol use disorders. Psychiatr Serv. 2008 Mar; 59(3):310-4. Leontieva L, Dimmock JA, Gately PW, Gallinger L, Ploutz-Snyder R, Batki SL. PMID: 18308913.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    41. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008; 22(11):903-16. Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, Owen R. PMID: 18840032.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    42. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am J Addict. 2007 Jul-Aug; 16(4):253-9. Batki SL, Dimmock JA, Wade M, Gately PW, Cornell M, Maisto SA, Carey KB, Ploutz-Snyder R. PMID: 17661192.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    43. Adapting Motivational Interventions for Comorbid Schizophrenia and Alcohol Use Disorders. Clin Psychol (New York). 2007 Mar; 14(1):39-57. Carey KB, Leontieva L, Dimmock J, Maisto SA, Batki SL. PMID: 19081784.
      View in: PubMed   Mentions: 2     Fields:    
    44. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007 Apr 17; 88(1):54-63. Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, Tulsky JP, Barnett P, Hall S. PMID: 17056206.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    45. Lamotrigine-associated rash and blood dyscrasias in a methadone-treatment patient with hepatitis C. Psychosomatics. 2006 May-Jun; 47(3):257-8. Alleyne S, Alao A, Batki SL. PMID: 16684944.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Rural jail telepsychiatry: a pilot feasibility study. Telemed J E Health. 2005 Oct; 11(5):574-7. Manfredi L, Shupe J, Batki SL. PMID: 16250821.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    47. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005 Sep; 11(5):315-39. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. PMID: 16184072.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    48. Fluoxetine attenuates adrenocortical but not subjective responses to cocaine cues. Am J Drug Alcohol Abuse. 2004 Nov; 30(4):765-82. Harris DS, Batki SL, Berger SP. PMID: 15624548.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    49. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Am J Addict. 2004 Oct-Dec; 13(5):461-70. Batki SL, Harris DS. PMID: 15764424.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    50. Comorbidity of bipolar disorder and substance abuse in Costa Rica: pedigree- and population-based studies. J Affect Disord. 2002 Sep; 71(1-3):71-83. Escamilla MA, Batki S, Reus VI, Spesny M, Molina J, Service S, Vinogradov S, Neylan T, Mathews C, Meza L, Gallegos A, Montero AP, Cruz ML, Neuhaus J, Roche E, Smith L, Leon P, Freimer NB. PMID: 12167503.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Review: dopamine agonists are not effective for cocaine dependence. Evid Based Ment Health. 2002 Aug; 5(3):82-3. Batki SL. PMID: 12180450.
      View in: PubMed   Mentions:    Fields:    
    52. Review: antidepressants are not effective for cocaine dependence. Evid Based Ment Health. 2002 Aug; 5(3):82-3. Batki SL. PMID: 12180449.
      View in: PubMed   Mentions:    Fields:    
    53. Genomewide linkage disequilibrium mapping of severe bipolar disorder in a population isolate. Am J Hum Genet. 2002 Sep; 71(3):565-74. Ophoff RA, Escamilla MA, Service SK, Spesny M, Meshi DB, Poon W, Molina J, Fournier E, Gallegos A, Mathews C, Neylan T, Batki SL, Roche E, Ramirez M, Silva S, De Mille MC, Dong P, Leon PE, Reus VI, Sandkuijl LA, Freimer NB. PMID: 12119601.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    54. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 2002 May 01; 66(3):283-93. Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. PMID: 12062463.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    55. Medical service use and financial charges among opioid users at a public hospital. Drug Alcohol Depend. 2002 Mar 01; 66(1):45-50. Masson CL, Sorensen JL, Batki SL, Okin R, Delucchi KL, Perlman DC. PMID: 11850135.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    56. Urine toxicology samples in cocaine treatment trials: how many need to be tested? J Addict Dis. 2002; 21(2):17-26. Delucchi KL, Batki SL, Moon J, Jacob P, Jones RT. PMID: 11916369.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    Steven's Networks
    Concepts (283)
    Derived automatically from this person's publications.
    Co-Authors (39)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department